CP reduced the pathological symptoms of ACD and reduced histological symptoms such as epidermal and dermal thickness, the infiltration of eosinophils, mast cells, CD4+ T cells, and CD8+ T cells in vivo. The gene discussed is CD8A; the disease is granular corneal dystrophy type II.